Security key
92765F108
Viracta Therapeutics, Inc. - Common Stock (VIRX)
CUSIP: 92765F108
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 171,747
- Total 13F value
- $3,796
- Share change
- -3,444,312
- SEC-reported price per share
- $0.02
- Number of holders
- 5
- Value change
- -$566,728
- Number of buys
- 2
- Number of sells
- 26
- Shares outstanding
- 19,711,628
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
5
Top holders
5
VIRX full security history
Ownership snapshot
Full 13F holder table
Viracta Therapeutics, Inc. SEC filings
Viracta Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of VIRX - Viracta Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FORWARD VENTURES V LP
Disclosed value leader
CITADEL ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 4.3%
13D/G row: FORWARD VENTURES V LP
Showing 1-6 of 15 holder rows.
Quick read
FORWARD VENTURES V LP leads the comparable SEC ownership view at 4.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FORWARD VENTURES V LP's linked filing trail.
Comparable ownership
Top 5
FORWARD VENTURES V LP
4.3%
CITADEL ADVISORS LLC
8.3%
VANGUARD GROUP INC
1.5%
Aisling Capital Management LP
1.5%
RENAISSANCE TECHNOLOGIES LLC
1.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FORWARD VENTURES V LP |
13D/G
|
4.3%
|
$16,952
847,600 shares
|
$0 | 31 Dec 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
8.3%
|
$261,665
1,626,258 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
1.5%
|
$46,557
289,174 shares
|
— | 31 Dec 2024 |
| Aisling Capital Management LP |
13F
Company
|
1.5%
|
$46,171
288,571 shares
|
— | 31 Dec 2024 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1.5%
|
$46,081
286,395 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
1.2%
|
$37,787
234,846 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
5
Shares
171,747
Rows available
5
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
5
Q1 2025 holders
5
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|